Ziconotide: a clinical update and pharmacologic review (Q38093859)

28 August 2017

Ziconotide: a clinical update and pharmacologic review (English)

1 reference

28 August 2017

1 reference

Jason E Pope

1

1 reference

PubMed ID

23537340

28 August 2017

Timothy R Deer

series ordinal

2

1 reference

PubMed ID

23537340

28 August 2017

language of work or name

English

0 references

publication date

28 March 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

1 reference

28 August 2017

14

1 reference

28 August 2017

7

1 reference

28 August 2017

957-966

1 reference

Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Autoradiographic localization of calcium channels with [125I]omega-conotoxin in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Ziconotide for treatment of severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Long-term intrathecal ziconotide for chronic pain: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Convection-enhanced delivery in the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Ziconotide: a review of its pharmacology and use in the treatment of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Cerebrospinal fluid flow imaging by using phase-contrast MR technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Recent insights into a new hydrodynamics of the cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

The influence of pulse and respiration on spinal cerebrospinal fluid pulsation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Morphine distribution in the spinal cord after chronic infusion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Measured density and calculated baricity of custom-compounded drugs for chronic intrathecal infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Intrathecal ziconotide for neuropathic pain: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Ziconotide for the treatment of severe spasticity after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Ziconotide combination intrathecal therapy: rationale and evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Chemical Stability of Admixtures Combining Ziconotide with Morphine or Hydromorphone During Simul ated Intrathecal Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Increased risk of suicide under intrathecal ziconotide treatment? - a warning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.784269

10.1517/14656566.2013.784269

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23537340